B&L Will Shift Optivar Reps To Anticipated New Product Launches In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps will support projected launches for ZyLET and Retisert following the end of a co-promotion agreement for MedPointe's Optivar. B&L expects action on the ZyLET NDA next year and on the Retisert application by year-end.